ASX ANNOUNCEMENT

10 November 2025

2025 Annual General Meeting

Chair and CEO Address

Sydney, Australia – Tetratherix Limited (ASX: TTX) advises that, in accordance with Listing Rule 3.13.3, it attaches the following documents to be delivered today at the 2025 Annual General Meeting:

- Chair's Address; and
- Chief Executive Officer's Address.

< ENDS >

Authorised for ASX release by the Board of Tetratherix Limited.

For further information, please contact:
Jacob Pfeffer
General Counsel
+61 425 194 200
jacob.pfeffer@tetratherix.com
https://tetratherix.com/

Chair's Address

Firstly, let me welcome all of our shareholders: both new shareholders who subscribed through the IPO and have bought Tetratherix shares on-market subsequently; and, of course, our long-term shareholders who have been on this journey with us over the years.

FY25 was a pivotal year in Tetratherix's history with the successful ASX listing at the end of June and, just four months on, we are pleased to confirm that the business is well on track to meet its targeted commercialisation strategies as outlined in the Prospectus, has adhered to the proposed use of funds and, in fact, has augmented the pace of commercialisation with the successful award of the previously announced IGP Grant.

Our CEO, Will Knox, will cover these points in further detail shortly.

The board remains focused on ensuring long-term shareholder value growth through the commercialisation of the Tetramatrix Platform. We acknowledge the need to balance the exciting commercial opportunities that are being developed with ensuring appropriate governance standards are in place and adhered to by each of the board, the founders, the executive team and the broader Tetratherix team.

Before I hand over to Will, I would like to take this opportunity to recognise the incredible work of the Tetratherix founders and the executive team who are a small but extremely dedicated and hard-working group and are all driven by the ultimate goal of providing significantly improved patient outcomes with our technology.

The executive team has worked incredibly well, in particular to maintain focus on the commercialisation activities whilst taking all the necessary steps involved in an IPO on the ASX.

They should be commended for their progress thus far - well done.

Speaking on behalf of the board, we look forward to continuing to support the journey of Tetratherix, I will now hand over to Will.

Chief Executive Officer's Address

Ladies and gentlemen, esteemed shareholders, dedicated team members, and valued partners, thank you for being here today for our Annual General Meeting.

At Tetratherix, our mission is clear and unwavering: to transform the lives of patients through groundbreaking medical solutions. Everything we do is rooted in the needs of patients. They are our guiding star, and our commitment to improving their outcomes drives our innovation and progress.

In just four short months since our listing, I am pleased to report that we have made significant technical and commercial strides. We stand at the precipice of multiple near-term catalysts that will propel us forward.

Our progress with the FDA on the bone franchise and tissue spacing is on track, and we are genuinely excited about the imminent commercialisation of these solutions. But for us and I hope the broader market, this is not just about approval; it's about the tangible impact these products will have on patients' lives.

Moreover, the IGP Grant we recently received is a testament to our advanced manufacturing capabilities. It recognises Tetratherix as a leading player in the Australian export landscape, positioning us to contribute significantly to our economy while enhancing healthcare globally.

We've also executed our license agreement with BioOptix - a leading US physician-led organisation. This partnership expands our tissue spacing franchise and aligns with our strategy to bring our innovative solutions to a broader market.

Our R&D efforts continue to propel us forward and I'm thrilled to confirm that the TetraDerm study is progressing through its cohorts on schedule. Additionally, as released in October, the early results from our Tutela clinical study are extremely promising. What is particularly remarkable is that we have taken Tutelix from a simple concept to clinical implementation in under 24 months - a demonstration of our unique platform and a true testament to our team's ingenuity and relentless pursuit of excellence.

Looking ahead, the TTX future is bright for all of our extended shareholders, partners and especially for our team. We are currently constructing our new facility that will significantly enhance our operational capabilities and is set to be fully functional by 2026. As communicated in our prospectus, this investment underscores our commitment to rapidly scaling our impact and ensuring that we have the resources necessary to deliver on our promise.

Following, I want to confirm that our allocation of funds remains aligned with our prospectus, with our additional funding from our IGP Grant enabling the acceleration of select strategic imperatives. Our healthy balance sheet positions us well for sustained growth over the next few years, allowing us to continue to innovate and expand our offerings in a rapidly evolving market.

I would be remiss if I didn't take a moment to express my heartfelt gratitude to all our investors. Your unwavering support is the bedrock of our success. To our board, thank you for your guidance and vision. And most importantly, to our amazing team: your hard work and dedication to keeping patients at the forefront of our mission is what drives us. You are the engine of this company, and it's your commitment that allows us to dream big and deliver meaningful solutions.

As we reflect on our journey and look ahead, let us remain steadfast in our mission: to improve lives through innovative healthcare solutions. Together, we are not just building a company; we are fostering a future where our work makes a real difference for patients around the world.